Novo Nordisk’s ZEUS Trial Fails Primary Endpoint in Cardiovascular Disease Study
Event summary
- ZEUS phase 3 trial of ziltivekimab failed to reduce major adverse cardiovascular events (MACE) in patients with ASCVD, CKD, and inflammation.
- The study enrolled over 6,300 participants and tested once-monthly ziltivekimab 15 mg against placebo.
- Ziltivekimab demonstrated target engagement but did not translate into clinical benefits for MACE reduction (hazard ratio: 0.99).
- Novo Nordisk will take a non-cash impairment charge in Q3 2026 due to the trial outcome.
- Two additional cardiovascular outcomes trials (HERMES and ARTEMIS) are ongoing and expected to read out in H1 2027.
The big picture
Novo Nordisk’s ZEUS trial outcome highlights the challenges in translating anti-inflammatory mechanisms into cardiovascular benefits, a critical area with significant unmet medical needs. The failure underscores the complexity of developing therapies targeting chronic inflammation in high-risk patient populations, particularly those with ASCVD and CKD. Despite this setback, Novo Nordisk remains committed to cardiovascular research, with ongoing trials expected to provide further insights.
What we're watching
- Pipeline Strategy
- Whether Novo Nordisk will reallocate resources from ziltivekimab to other cardiovascular or inflammation-focused therapies.
- Regulatory Impact
- How regulatory agencies may interpret these results and their potential influence on future trial designs in this space.
- Financial Implications
- The magnitude of the non-cash impairment charge and its effect on Novo Nordisk’s financial guidance for 2026.
Related topics